Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)
The FDA cleared Rocket Pharma to resume its gene therapy trial for Danon disease after a patient death halted the study in May; the trial will restart with a lower dose and without the immune-suppressing drug linked to the fatal complication. Rocket shares jumped over 30% after the decision. Early data showed Dynavax’s shingles vaccine matched GSK’s Shingrix in immune response but caused fewer side effects, sending Dynavax shares up 7%.
